Holen Sie sich die Stockscreener-App
22.93
1.64%
0.37
Handel nachbörslich:
22.53
-0.40
-1.74%
Schlusskurs vom Vortag:
$22.56
Offen:
$22.16
24-Stunden-Volumen:
1.13M
Relative Volume:
1.44
Marktkapitalisierung:
$2.57B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-10.67
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+9.09%
1M Leistung:
+27.67%
6M Leistung:
-1.88%
1J Leistung:
+20.68%
1-Tages-Spanne:
$22.00
$22.98
1-Wochen-Bereich:
$20.53
$23.04
52-Wochen-Spanne:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.93 | 2.36B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
What drives NewAmsterdam Pharma Company N.V. stock priceRapid wealth creation - Autocar Professional
What makes NewAmsterdam Pharma Company N.V. stock price move sharplyDaily Breakout Picks - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant Stock Analysis and ForecastHigh-impact stock picks - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025 - GlobeNewswire
Major Alzheimer's Discovery: Cardiovascular Drug Shows Promising Brain Health Benefits in 1,727 Patients - Stock Titan
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceHigh-yield capital appreciation - jammulinksnews.com
What analysts say about NewAmsterdam Pharma Company N.V. stockRapid return acceleration - jammulinksnews.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatilityFree High-Profit Stock Picks - Newser
What analysts say about NewAmsterdam Pharma Company N.V. Equity Warrant stockExtraordinary performance - jammulinksnews.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant a good long term investmentExceptional return forecasts - Autocar Professional
Is NewAmsterdam Pharma Company N.V. a good long term investmentExplosive portfolio gains - jammulinksnews.com
why newamsterdam pharma company n.v. equity warrant stock attracts strong analyst attentionFree Risk Assessment Services - Newser
When is the best time to buy NewAmsterdam Pharma Company N.V. stockFree Access to Investment Community - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs Group - Defense World
How NewAmsterdam Pharma Company N.V. stock reacts to Fed policy changesFree Capital Allocation Plans - Newser
Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com Nigeria
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $42.89 Consensus Price Target from Analysts - Defense World
Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionWatchlist Winner Update - Newser
Why NewAmsterdam Pharma Company N.V. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How NewAmsterdam Pharma Company N.V. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyAlpha Stock Ideas - Newser
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):